Ignite Creation Date:
2024-05-06 @ 4:34 PM
Last Modification Date:
2024-10-26 @ 2:12 PM
Study NCT ID:
NCT05027100
Status:
UNKNOWN
Last Update Posted:
2022-07-01
First Post:
2021-08-22
Brief Title:
Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC
Sponsor:
Organization:
Guangzhou University of Traditional Chinese Medicine